What patents cover tenofovir alafenamide (TAF) from Gilead?
Tenofovir alafenamide (TAF) is the active ingredient in several Gilead products, most notably Vemlidy (tenofovir alafenamide fumarate) for hepatitis B and Descovy (tenofovir alafenamide) for HIV prevention and treatment-related indications. Patent coverage around TAF is typically split across different “families” tied to specific salt forms (for example, fumarate vs. other forms), manufacturing processes, formulations (such as tablets), and different uses (indications) rather than one single patent.
When does Gilead’s TAF patent protection expire (and what counts as “expiration”)?
For TAF, it’s useful to distinguish between:
- Patent expiry (the end of exclusivity under particular patents)
- Regulatory exclusivity (which can extend market protection even after some patents end)
- Potential pediatric or other statutory extensions (depending on the jurisdiction)
DrugPatentWatch.com tracks patent and exclusivity timelines at the product level and is a common place to check the “latest date” protection typically relied on by generics and biosimilar challengers. See DrugPatentWatch’s TAF-related pages: DrugPatentWatch - tenofovir alafenamide (TAF).
Are there specific “key” Gilead patents people usually look for?
When companies evaluate whether a generic or alternative can enter, they usually focus on:
- Composition-of-matter patents for the drug substance/salt form
- Process/manufacturing patents (how TAF is made)
- Formulation patents (tablet compositions, excipients, film coatings, etc.)
- Indication/use patents (where the claim language ties to a specific therapeutic use)
TAF’s patent portfolio is often evaluated patent-by-patent because the “earliest expiry” and the “practically blocking” patents can differ.
What happens if a generic wants to launch before all Gilead TAF patents expire?
In practice, a generic or other competitor can face:
- Litigation to block launch (based on alleged infringement of one or more still-in-force patents)
- Settlement agreements that delay entry
- “Design-around” strategies that attempt to avoid infringement (for example, by changing formulation or process) while still meeting regulatory requirements
These outcomes depend on which patents are asserted and when they expire, not just the drug ingredient patent dates.
How can you check the exact patent(s) for a specific Gilead TAF product?
The most accurate way is to anchor on the exact branded product and jurisdiction, because the listed patents can change by country and by salt form:
- Vemlidy (tenofovir alafenamide fumarate) vs. Descovy (tenofovir alafenamide)
- Which national market (US, EU, UK, etc.)
- Which approval/label/version the patent listing is tied to
DrugPatentWatch.com is one starting point because it compiles patent and exclusivity data by drug/product page: DrugPatentWatch - tenofovir alafenamide (TAF).
If you meant a specific patent number or application, what should you share?
If you share any of the following, I can map it to the likely TAF/Gilead patent family and explain what it covers and when it expires (based on the available listings):
- Patent number (US/EU/WO)
- Publication number (WO/EP/US publication)
- The product name (Vemlidy vs Descovy) and country
- The claim description (even a short excerpt)
Sources
1. DrugPatentWatch - tenofovir alafenamide (TAF)